title: Cetuximab in small bowel adenocarcinoma: a new friend?
authors.forename: D
authors.initials: D
authors.lastname: Santini
authors.forename: M E
authors.initials: ME
authors.lastname: Fratto
authors.forename: C
authors.initials: C
authors.lastname: Spoto
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: S
authors.initials: S
authors.lastname: Galluzzo
authors.forename: A
authors.initials: A
authors.lastname: Zoccoli
authors.forename: B
authors.initials: B
authors.lastname: Vincenzi
authors.forename: G
authors.initials: G
authors.lastname: Tonini
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007414:Intestinal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D007421:Intestine, Small / Q000473:pathology; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D013534:Survival
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin